Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants
ABSTRACT Purpose: To evaluate the effectiveness of intravitreal bevacizumab injections following a single dexamethasone implant in the treatment of macular edema secondary to branch and central retinal vein occlusion. Methods: This was a prospective interventional non-comparative study, 44 eyes of p...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Dataset |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Moreno-López, María de-Arriba-Palomero, Pablo de-Arriba-Palomero, Fernando Ituruburu, Federico Peralta Dompablo, Elisabet de Negrete, Francisco José Muñoz |
| description | ABSTRACT Purpose: To evaluate the effectiveness of intravitreal bevacizumab injections following a single dexamethasone implant in the treatment of macular edema secondary to branch and central retinal vein occlusion. Methods: This was a prospective interventional non-comparative study, 44 eyes of patients with naïve macular edema related to branch and central retinal vein occlusion were treated with a dexamethasone implant. Patients were followed-up at four-week intervals from the second to the sixth month. If persistent or recurrent macular edema occurred during this period, the patient was treated with intravitreal bevacizumab injections on an as-needed basis. The outcome measures were best-corrected visual acuity and central macular thickness changes. Results: The mean best-corrected visual acuity changed from 0.97 ± 0.33 LogMAR at baseline to 0.54 ± 0.40 at the six-month post-implant examination (p |
| doi_str_mv | 10.6084/m9.figshare.23300516 |
| format | Dataset |
| fullrecord | <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_23300516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_23300516</sourcerecordid><originalsourceid>FETCH-LOGICAL-d916-6cee048f590ec5e46418ce86fba24904d9731b55e3ed74a24450c6b65d822cd43</originalsourceid><addsrcrecordid>eNo1kMtqwzAQRb3poqT9gy70A05lW1LsZQl9QaBdZG_G0qgW6BEk2X38VH-xNmlWA2fg3JlbFHcV3QrasnvXbbX5SCNE3NZNQymvxHXx-x5DOqHMZkaCM9gJsgmeBE3yuBCtzzuPKa1QBjcYj4rkiJAd-rxSB3KyEAkqdEASyuAVxG-SA4mYjQdLZjSLVUo7pdX_afJIjM8RZrOqLBmWdGl-JgcDAa-Iwi9wmEdIwSMx7mTB53RTXGmwCW__56Y4Pj0e9y_l4e35df9wKFVXiVJIRMpazTuKkiMTrGoltkIPULOOMtXtmmrgHBtUO7YwxqkUg-CqrWupWLMp2FmrIC9XZexP0bjlpb6i_Vpn77r-Umd_qbP5A75Td5w</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>dataset</recordtype></control><display><type>dataset</type><title>Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants</title><source>DataCite</source><creator>Moreno-López, María ; de-Arriba-Palomero, Pablo ; de-Arriba-Palomero, Fernando ; Ituruburu, Federico Peralta ; Dompablo, Elisabet de ; Negrete, Francisco José Muñoz</creator><creatorcontrib>Moreno-López, María ; de-Arriba-Palomero, Pablo ; de-Arriba-Palomero, Fernando ; Ituruburu, Federico Peralta ; Dompablo, Elisabet de ; Negrete, Francisco José Muñoz</creatorcontrib><description>ABSTRACT Purpose: To evaluate the effectiveness of intravitreal bevacizumab injections following a single dexamethasone implant in the treatment of macular edema secondary to branch and central retinal vein occlusion. Methods: This was a prospective interventional non-comparative study, 44 eyes of patients with naïve macular edema related to branch and central retinal vein occlusion were treated with a dexamethasone implant. Patients were followed-up at four-week intervals from the second to the sixth month. If persistent or recurrent macular edema occurred during this period, the patient was treated with intravitreal bevacizumab injections on an as-needed basis. The outcome measures were best-corrected visual acuity and central macular thickness changes. Results: The mean best-corrected visual acuity changed from 0.97 ± 0.33 LogMAR at baseline to 0.54 ± 0.40 at the six-month post-implant examination (p<0.00001). Improvement ≥3 Snellen lines were seen in 20 eyes (45.54%). The mean central macular thickness at baseline was 670.25 ± 209.9 microns. This had decreased to 317.43 ± 112.68 microns at the six-month follow-up (p<0.00001). The mean number of intravitreal bevacizumab injections received in the six months post-implant was 2.32. The mean time from dexamethasone implant to first anti-VEGF injection was 3.45 months. Conclusions: Intravitreal bevacizumab injections following a single dexamethasone implant were found to improve best-corrected visual acuity and central macular thickness in patients with macular edema due to branch and central retinal vein occlusion at six months, with few intravitreal injections required.</description><identifier>DOI: 10.6084/m9.figshare.23300516</identifier><language>eng</language><publisher>SciELO journals</publisher><subject>FOS: Clinical medicine ; Ophthalmology</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,1888</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.23300516$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Moreno-López, María</creatorcontrib><creatorcontrib>de-Arriba-Palomero, Pablo</creatorcontrib><creatorcontrib>de-Arriba-Palomero, Fernando</creatorcontrib><creatorcontrib>Ituruburu, Federico Peralta</creatorcontrib><creatorcontrib>Dompablo, Elisabet de</creatorcontrib><creatorcontrib>Negrete, Francisco José Muñoz</creatorcontrib><title>Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants</title><description>ABSTRACT Purpose: To evaluate the effectiveness of intravitreal bevacizumab injections following a single dexamethasone implant in the treatment of macular edema secondary to branch and central retinal vein occlusion. Methods: This was a prospective interventional non-comparative study, 44 eyes of patients with naïve macular edema related to branch and central retinal vein occlusion were treated with a dexamethasone implant. Patients were followed-up at four-week intervals from the second to the sixth month. If persistent or recurrent macular edema occurred during this period, the patient was treated with intravitreal bevacizumab injections on an as-needed basis. The outcome measures were best-corrected visual acuity and central macular thickness changes. Results: The mean best-corrected visual acuity changed from 0.97 ± 0.33 LogMAR at baseline to 0.54 ± 0.40 at the six-month post-implant examination (p<0.00001). Improvement ≥3 Snellen lines were seen in 20 eyes (45.54%). The mean central macular thickness at baseline was 670.25 ± 209.9 microns. This had decreased to 317.43 ± 112.68 microns at the six-month follow-up (p<0.00001). The mean number of intravitreal bevacizumab injections received in the six months post-implant was 2.32. The mean time from dexamethasone implant to first anti-VEGF injection was 3.45 months. Conclusions: Intravitreal bevacizumab injections following a single dexamethasone implant were found to improve best-corrected visual acuity and central macular thickness in patients with macular edema due to branch and central retinal vein occlusion at six months, with few intravitreal injections required.</description><subject>FOS: Clinical medicine</subject><subject>Ophthalmology</subject><fulltext>true</fulltext><rsrctype>dataset</rsrctype><creationdate>2023</creationdate><recordtype>dataset</recordtype><sourceid>PQ8</sourceid><recordid>eNo1kMtqwzAQRb3poqT9gy70A05lW1LsZQl9QaBdZG_G0qgW6BEk2X38VH-xNmlWA2fg3JlbFHcV3QrasnvXbbX5SCNE3NZNQymvxHXx-x5DOqHMZkaCM9gJsgmeBE3yuBCtzzuPKa1QBjcYj4rkiJAd-rxSB3KyEAkqdEASyuAVxG-SA4mYjQdLZjSLVUo7pdX_afJIjM8RZrOqLBmWdGl-JgcDAa-Iwi9wmEdIwSMx7mTB53RTXGmwCW__56Y4Pj0e9y_l4e35df9wKFVXiVJIRMpazTuKkiMTrGoltkIPULOOMtXtmmrgHBtUO7YwxqkUg-CqrWupWLMp2FmrIC9XZexP0bjlpb6i_Vpn77r-Umd_qbP5A75Td5w</recordid><startdate>20230606</startdate><enddate>20230606</enddate><creator>Moreno-López, María</creator><creator>de-Arriba-Palomero, Pablo</creator><creator>de-Arriba-Palomero, Fernando</creator><creator>Ituruburu, Federico Peralta</creator><creator>Dompablo, Elisabet de</creator><creator>Negrete, Francisco José Muñoz</creator><general>SciELO journals</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20230606</creationdate><title>Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants</title><author>Moreno-López, María ; de-Arriba-Palomero, Pablo ; de-Arriba-Palomero, Fernando ; Ituruburu, Federico Peralta ; Dompablo, Elisabet de ; Negrete, Francisco José Muñoz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d916-6cee048f590ec5e46418ce86fba24904d9731b55e3ed74a24450c6b65d822cd43</frbrgroupid><rsrctype>datasets</rsrctype><prefilter>datasets</prefilter><language>eng</language><creationdate>2023</creationdate><topic>FOS: Clinical medicine</topic><topic>Ophthalmology</topic><toplevel>online_resources</toplevel><creatorcontrib>Moreno-López, María</creatorcontrib><creatorcontrib>de-Arriba-Palomero, Pablo</creatorcontrib><creatorcontrib>de-Arriba-Palomero, Fernando</creatorcontrib><creatorcontrib>Ituruburu, Federico Peralta</creatorcontrib><creatorcontrib>Dompablo, Elisabet de</creatorcontrib><creatorcontrib>Negrete, Francisco José Muñoz</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Moreno-López, María</au><au>de-Arriba-Palomero, Pablo</au><au>de-Arriba-Palomero, Fernando</au><au>Ituruburu, Federico Peralta</au><au>Dompablo, Elisabet de</au><au>Negrete, Francisco José Muñoz</au><format>book</format><genre>unknown</genre><ristype>DATA</ristype><title>Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants</title><date>2023-06-06</date><risdate>2023</risdate><abstract>ABSTRACT Purpose: To evaluate the effectiveness of intravitreal bevacizumab injections following a single dexamethasone implant in the treatment of macular edema secondary to branch and central retinal vein occlusion. Methods: This was a prospective interventional non-comparative study, 44 eyes of patients with naïve macular edema related to branch and central retinal vein occlusion were treated with a dexamethasone implant. Patients were followed-up at four-week intervals from the second to the sixth month. If persistent or recurrent macular edema occurred during this period, the patient was treated with intravitreal bevacizumab injections on an as-needed basis. The outcome measures were best-corrected visual acuity and central macular thickness changes. Results: The mean best-corrected visual acuity changed from 0.97 ± 0.33 LogMAR at baseline to 0.54 ± 0.40 at the six-month post-implant examination (p<0.00001). Improvement ≥3 Snellen lines were seen in 20 eyes (45.54%). The mean central macular thickness at baseline was 670.25 ± 209.9 microns. This had decreased to 317.43 ± 112.68 microns at the six-month follow-up (p<0.00001). The mean number of intravitreal bevacizumab injections received in the six months post-implant was 2.32. The mean time from dexamethasone implant to first anti-VEGF injection was 3.45 months. Conclusions: Intravitreal bevacizumab injections following a single dexamethasone implant were found to improve best-corrected visual acuity and central macular thickness in patients with macular edema due to branch and central retinal vein occlusion at six months, with few intravitreal injections required.</abstract><pub>SciELO journals</pub><doi>10.6084/m9.figshare.23300516</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | DOI: 10.6084/m9.figshare.23300516 |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_datacite_primary_10_6084_m9_figshare_23300516 |
| source | DataCite |
| subjects | FOS: Clinical medicine Ophthalmology |
| title | Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A22%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Moreno-L%C3%B3pez,%20Mar%C3%ADa&rft.date=2023-06-06&rft_id=info:doi/10.6084/m9.figshare.23300516&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_23300516%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |